%0 Journal Article
%T Pulmonary arteriovenous malformations: endovascular therapy
%A Daniel Lamus
%A Girish Kumar
%A Harold Park
%A Matthew Anderson
%A Murthy R. Chamarthy
%A Patrick Sutphin
%A Sachin Saboo
%A Sanjeeva P. Kalva
%J SCIE-indexed Journal
%D 2018
%X The natural course of pulmonary arteriovenous malformations (PAVM) is not well studied but most of the lesions remain either stable (75%) or demonstrate slow growth (25%) (1,2). However, untreated PAVM are associated with a high risk of morbidity and mortality (0¨C55%) compared to 3% in the treated patients (1,3). Prompt identification and treatment are indicated given the high risk of complications such as brain abscess (9%), cerebrovascular accident (2.6¨C25%), hemoptysis/hemothorax (8%), and hypoxemic respiratory failure (1,4-6). The risk of neurological complications has been shown to be higher with diffuse type of PAVM, a large shunt, and a feeding arterial diameter (FAD) of greater than 3 mm (7,8). Additionally, there is decreased risk of neurological complications in treated PAVM. When feasible, endovascular embolotherapy is the mainstay of treatment with less morbidity and mortality (9). Surgical resection is rarely needed and is indicated for lesions that remain refractory to endovascular therapy or when endovascular treatment is not feasible. Lung transplant is indicated only for severe bilateral diffuse disease
%U http://cdt.amegroups.com/article/view/17992/19914